Peptides for Long COVID: What the Research Actually Shows

Long COVID — formally known as post-acute sequelae of SARS-CoV-2 (PASC) — affects an estimated 5-10% of people who contract COVID-19. Symptoms range from debilitating fatigue and cognitive impairment to persistent respiratory issues, cardiovascular dysfunction, and immune dysregulation. The condition's multi-system nature has driven interest in peptide-based interventions that can address multiple pathological mechanisms simultaneously.

This article examines the specific peptides that have generated research attention for long COVID, evaluates the actual evidence behind each, and distinguishes between laboratory findings, clinical observations, and wishful thinking.

Understanding long COVID's mechanisms

Before evaluating peptide interventions, it helps to understand the primary hypotheses for why long COVID persists. Current research points to several overlapping mechanisms:

• Viral persistence — fragments of SARS-CoV-2 RNA and spike protein have been detected in tissues months after acute infection
• Immune dysregulation — including T-cell exhaustion, elevated inflammatory cytokines, and autoantibody formation
• Mitochondrial dysfunction — impaired cellular energy production, particularly in muscle and neural tissue
• Endothelial damage — persistent injury to blood vessel linings, contributing to microclotting and reduced perfusion
• Neuroinflammation — microglial activation in the brain driving cognitive symptoms

Different peptides address different nodes in this web of dysfunction, which is why multi-peptide approaches have gained practitioner interest.

BPC-157: tissue repair and vascular recovery

BPC-157's relevance to long COVID rests on two of its well-established preclinical properties: tissue repair and vascular protection. The peptide promotes angiogenesis through VEGFR2 activation and modulates the nitric oxide system — both directly relevant to the endothelial damage and perfusion deficits seen in long COVID.

In animal models, BPC-157 has demonstrated protective effects against pulmonary injury, including reducing inflammatory infiltrates and preserving alveolar structure. Its promotion of new blood vessel formation could theoretically address the microvascular damage that contributes to exercise intolerance and organ dysfunction in long COVID patients.

However, no controlled studies have tested BPC-157 specifically in post-COVID contexts. Practitioner reports suggest some patients experience improved exercise tolerance and reduced joint pain with standard BPC-157 protocols (250-500 mcg subcutaneously, once or twice daily), but these observations lack controls and blinding. The mechanistic rationale is sound; the clinical validation is absent.

Thymosin alpha-1: resetting immune dysregulation

Thymosin alpha-1 (Ta1) is arguably the strongest candidate on this list from an evidence standpoint. It is an approved drug in multiple countries for viral hepatitis, and it was actually used during the acute COVID-19 pandemic in clinical settings. Published studies from early pandemic treatment protocols in China reported that Ta1 administration was associated with reduced mortality in severe COVID-19 patients, improved T-cell counts, and faster viral clearance.

For long COVID specifically, Ta1's mechanism addresses a core problem: T-cell exhaustion and immune dysregulation. The peptide promotes the maturation and differentiation of T cells in the thymus, supports natural killer cell activity, and enhances dendritic cell function. In long COVID patients who show persistent lymphopenia or impaired T-cell responses, Ta1 offers a mechanistic fit that few other interventions match.

Clinical protocols for Ta1 in post-COVID immune recovery typically involve 1.6 mg subcutaneously, two to three times per week, for 4-12 weeks. Some practitioners monitor lymphocyte subsets and inflammatory markers (CRP, IL-6, TNF-alpha) to assess response. While formal randomized controlled trials for Ta1 in long COVID are limited, the existing safety profile from decades of clinical use in other indications provides more confidence than most research peptides.

Selank: addressing post-COVID brain fog

Cognitive impairment — commonly called brain fog — is one of the most persistent and functionally disabling symptoms of long COVID. Selank is a synthetic peptide analogue of the endogenous immunomodulatory peptide tuftsin, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences.

Selank's dual mechanism makes it relevant to post-COVID neurological symptoms. It modulates brain-derived neurotrophic factor (BDNF) expression, which supports neuroplasticity and neuronal survival. Simultaneously, it influences the expression of IL-6 and other inflammatory mediators in brain tissue, potentially dampening the neuroinflammation that drives cognitive symptoms.

In preclinical studies, selank has shown anxiolytic effects comparable to benzodiazepines without sedation or dependence, improved memory consolidation, and enhanced attention in stressed animals. It is administered intranasally, typically at doses of 250-500 mcg per nostril, one to three times daily. The nasal route bypasses the blood-brain barrier to some degree, delivering the peptide more directly to CNS tissue.

The limitation is clear: while the mechanism is compelling for brain fog, no published studies have evaluated selank specifically in long COVID cognitive impairment. Practitioner reports from integrative clinics describe subjective improvements in mental clarity and reduced anxiety, but these remain anecdotal.

LL-37: targeting persistent viral fragments

LL-37 (cathelicidin) is the only human antimicrobial peptide in its class — a 37-amino-acid peptide that forms part of the innate immune system's first line of defense. It has direct antiviral activity, disrupting viral envelopes and interfering with viral attachment to host cells. LL-37 also modulates the inflammatory response, promoting pathogen clearance while limiting excessive tissue damage.

The hypothesis for LL-37 in long COVID is straightforward: if persistent viral fragments or reservoirs contribute to ongoing symptoms, an antimicrobial peptide that targets viral remnants while supporting immune clearance could address the root cause. Published research has demonstrated LL-37's activity against respiratory viruses including influenza and respiratory syncytial virus. Its activity against SARS-CoV-2 specifically has been explored in laboratory studies, with some data showing it can interfere with spike protein binding to ACE2 receptors.

LL-37 is typically administered subcutaneously at doses of 50-100 mcg daily in practitioner protocols. The peptide's tendency to cause injection site reactions and its relatively short half-life are practical limitations. No clinical trials have tested LL-37 for long COVID specifically.

SS-31 (elamipretide): mitochondrial rescue

Mitochondrial dysfunction is increasingly recognized as a central feature of long COVID. Patients commonly show reduced exercise capacity, elevated lactate at low workloads, and impaired oxygen utilization — all consistent with dysfunctional cellular energy production.

SS-31 (also known as elamipretide or Bendavia) is a mitochondria-targeted tetrapeptide that concentrates in the inner mitochondrial membrane, where it stabilizes cardiolipin — a phospholipid critical for electron transport chain function. By restoring cardiolipin organization, SS-31 improves ATP production efficiency and reduces reactive oxygen species generation.

SS-31 has undergone human clinical trials for other conditions involving mitochondrial dysfunction, including Barth syndrome and heart failure, providing some safety and pharmacokinetic data in humans. For long COVID, the rationale is compelling: if mitochondrial damage is driving fatigue and exercise intolerance, a peptide that directly rescues mitochondrial function addresses the mechanism rather than masking the symptom.

However, SS-31 is not commercially available through standard peptide suppliers. Access is limited to clinical trial settings and specialized compounding. This practical barrier limits its use despite the strong mechanistic case.

Combining approaches: multi-peptide protocols

Given that long COVID involves multiple simultaneous pathologies, some practitioners employ combination protocols. A common framework addresses three layers:

• Immune reset with thymosin alpha-1 as the foundation
• Tissue repair with BPC-157 for vascular and organ recovery
• Neurological support with selank for cognitive symptoms

These combinations are based on non-overlapping mechanisms and are generally considered compatible from a pharmacological standpoint. However, combination protocols multiply the uncertainty — if five peptides are used simultaneously and a patient improves, identifying which intervention drove the improvement is impossible without systematic withdrawal.

What the evidence actually supports

Honesty demands a clear-eyed summary. Thymosin alpha-1 has the strongest evidence base, with actual clinical use during the pandemic and decades of safety data. BPC-157 and selank have strong mechanistic rationales but no COVID-specific clinical trials. LL-37 and SS-31 are mechanistically interesting but face practical access limitations and thin clinical data for this application.

Long COVID patients considering peptide interventions should work with practitioners who will monitor objective markers — not just symptoms — and who will design protocols that can be systematically evaluated. The complexity of long COVID demands humility, not certainty, from everyone involved in treatment.